去纤维钠怎么保存?
On March 30, 2016, the FDA approved Defitelio (Defitelio) for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).
Hepatic veno-occlusive disease is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe hepatic veno-occlusive disease can be as high as 100%. Defibrotide sodium is a mixture of single-stranded oligonucleotides with anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defibrination sodium is a safe and effective drug for the prevention and treatment of hepatic veno-occlusive disease after HSCT.
The recommended dose of defibrotide sodium for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. Give sodium defibrate (defibrotide) for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrination until resolution of VOD or up to a maximum of 60 days. Must be diluted before infusion.
Defibrotide sodium is not currently on the market in my country, and patients have to face the problem of how to store it when buying the overseas version of the drug. Defibrotide sodium is an injection and is stored in an environment of 20°C-25°C (68°F-77°F); it is allowed to drift between 15°C and 30°C (59°F to 86°F). When stored at room temperature, diluted defibrinated sodium should be used within 4 hours. It is best to keep defibrinated sodium (defibrotide) out of the reach of children to avoid accidental ingestion.
Because of its mechanism of action, before administering defibrinated sodium, ensure that the patient has not experienced clinically significant bleeding and is hemodynamically stable to no more than one vasopressin. Do not coadminister it with other intravenous drugs simultaneously in the same intravenous line.
Recommended related hot articles: /newsDetail/71720.html
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)